APA (7th ed.) Citation

Long, G. V., Saw, R. P. M., Lo, S., Nieweg, O. E., Shannon, K. F., Gonzalez, M., . . . Spillane, A. J. (2019). Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): A single-arm, open-label, single-centre, phase 2 trial. Lancet Oncology, 20(7), 961. https://doi.org/10.1016/S1470-2045(19)30331-6

Chicago Style (17th ed.) Citation

Long, Georgina V., et al. "Neoadjuvant Dabrafenib Combined with Trametinib for Resectable, Stage IIIB-C, BRAFV600 Mutation-positive Melanoma (NeoCombi): A Single-arm, Open-label, Single-centre, Phase 2 Trial." Lancet Oncology 20, no. 7 (2019): 961. https://doi.org/10.1016/S1470-2045(19)30331-6.

MLA (9th ed.) Citation

Long, Georgina V., et al. "Neoadjuvant Dabrafenib Combined with Trametinib for Resectable, Stage IIIB-C, BRAFV600 Mutation-positive Melanoma (NeoCombi): A Single-arm, Open-label, Single-centre, Phase 2 Trial." Lancet Oncology, vol. 20, no. 7, 2019, p. 961, https://doi.org/10.1016/S1470-2045(19)30331-6.